Is liver disease a threat to patients with metabolic disorders?

References

• Tolman K. G., Fonseca V., Tan M. H., Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004; 141: 946–56
   Google Scholar
• Ludwig J., Viaggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–8
   PubMed Web of Science ®Google Scholar
• Falck‐Ytter Y., Younossi Z. M., Marchesini G., McCullough A. J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17–26
   PubMed Web of Science ®Google Scholar
• Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40
   PubMed Web of Science ®Google Scholar
• Mokdad A. H., Ford E. S., Bowman B. A., Dietz W. H., Vinicor F., Bales V. S., et al. Prevalence of obesity, diabetes, and obesity‐related health risk factors, 2001. JAMA 2003; 289: 76–9
   PubMed Web of Science ®Google Scholar
• Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23
   PubMed Web of Science ®Google Scholar
• Mofrad P., Contos M. J., Haque M., Sargeant C., Fisher R. A., Luketic V. A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286–92
   PubMed Web of Science ®Google Scholar
• Marchesini G., Brizi M., Morselli‐Labate A. M., Bianchi G., Bugianesi E., McCullough A. J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5
   PubMed Web of Science ®Google Scholar
• Cortez‐Pinto H., Camilo M. E., Baptista A., De Oliveira A. G., De Moura M. C. Non‐alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 1999; 18: 353–8
   PubMed Web of Science ®Google Scholar
• Chitturi S., Abeygunasekera S., Farrell G. C., Holmes‐Walker J., Hui J., Fung C., et al. NASH and insulin resistance: insulin secretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373–9
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97
   PubMed Web of Science ®Google Scholar
• Kim H. J., Lee K. E., Kim D. J., Kim S. K., Ahn C. W., Lim S. K., et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169–75
   PubMedGoogle Scholar
• Bianchi G., Marchesini G., Zoli M., Bugianesi E., Fabbri A., Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119–25
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W., Frerichs H., Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970; 3: 371–407
   PubMedGoogle Scholar
• Kumar K. S., Malet P. F. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000; 75: 733–9
   Google Scholar
• Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31
   PubMed Web of Science ®Google Scholar
• Clark J. M., Brancati F. L., Diehl A. M. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649–57
   PubMed Web of Science ®Google Scholar
• Saverymuttu S. H., Joseph A. E., Maxwell J. D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. BMJ 1986; 292: 13–5
   PubMed Web of Science ®Google Scholar
• Ricci C., Longo R., Gioulis E., Bosco M., Pollesello P., Masutti F., et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27: 108–13
   PubMed Web of Science ®Google Scholar
• Jick S. S., Stender M., Myers M. W. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999; 22: 2067–71
   PubMed Web of Science ®Google Scholar
• El‐Serag H. B., Tran T., Everhart J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460–8
   PubMed Web of Science ®Google Scholar
• Ohlson L. O., Larsson B., Bjorntorp P., Eriksson H., Svardsudd K., Welin L., et al. Risk factors for type 2 (non‐insulin‐dependent) diabetes mellitus. Thirteen and one‐half years of follow‐up of the participants in a study of Swedish men born in 1913. Diabetologia 1988; 31: 798–805
   PubMed Web of Science ®Google Scholar
• Vozarova B., Stefan N., Lindsay R. S., Saremi A., Pratley R. E., Bogardus C., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889–95
   PubMed Web of Science ®Google Scholar
• Perry I. J., Wannamethee S. G., Shaper A. G. Prospective study of serum gamma‐glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 732–7
   PubMed Web of Science ®Google Scholar
• Hanley A. J., Williams K., Festa A., Wagenknecht L. E., D'Agostino R. B, Jr., Kempf J., et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623–32
   PubMed Web of Science ®Google Scholar
• Bellentani S., Saccoccio G., Masutti F., Croce L. S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112–7
   PubMed Web of Science ®Google Scholar
• Marceau P., Biron S., Hould F. S., Marceau S., Simard S., Thung S. N., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513–7
   PubMed Web of Science ®Google Scholar
• Dixon J. B., Bhathal P. S., O'Brien P. E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91–100
   PubMed Web of Science ®Google Scholar
• Ratziu V., Giral P., Charlotte F., Bruckert E., Thibault V., Theodorou I., et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117–23
   PubMed Web of Science ®Google Scholar
• Silverman J. F., Pories W. J., Caro J. F. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989; 24: 275–302
   PubMed Web of Science ®Google Scholar
• Silverman J. F., O'Brien K. F., Long S., Leggett N., Khazanie P. G., Pories W. J., et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349–55
   PubMed Web of Science ®Google Scholar
• Clark J. M., Brancati F. L., Diehl A. M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960–7
   PubMed Web of Science ®Google Scholar
• Ruhl C. E., Everhart J. E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71–9
   PubMed Web of Science ®Google Scholar
• Hsiao T. J., Chen J. C., Wang J. D. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004; 28: 167–72
   PubMed Web of Science ®Google Scholar
• Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1–10
   PubMed Web of Science ®Google Scholar
• Stranges S., Dorn J. M., Muti P., Freudenheim J. L., Farinaro E., Russell M., et al. Body fat distribution, relative weight, and liver enzyme levels: A population‐based study. Hepatology 2004; 39: 754–63
   PubMedGoogle Scholar
• Assy N., Kaita K., Mymin D., Levy C., Rosser B., Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929–34
   PubMed Web of Science ®Google Scholar
• Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli‐Labate A. M., Rasciti L., et al. Increased prevalence of fatty liver in arterial hypertensive patients. Role of insulin resistance. Gut 2004; 53: 1020–3
   PubMed Web of Science ®Google Scholar
• Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M. A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7
   PubMed Web of Science ®Google Scholar
• Jeong S. K., Nam H. S., Rhee J. A., Shin J. H., Kim J. M., Cho K. H. Metabolic syndrome and ALT: a community study in adult Koreans. Int J Obes Relat Metab Disord 2004; 28: 1033–8
   Google Scholar
• Marchesini G., Avagnina S., Barantani E. G., Ciccarone A. M., Corica F., Dall'Aglio E., et al. Aminotransferase and gamma‐glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005; 28: 333–9
   PubMed Web of Science ®Google Scholar
• Marchesini G., Bugianesi E., Forlani G., Marzocchi R., Zannoni C., Vanni E., et al. Non‐alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res Clin Pract 2004; 63: 143–51
   Google Scholar
• Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179–87
   PubMed Web of Science ®Google Scholar
• Papadia F. S., Marinari G. M., Camerini G., Murelli F., Carlini F., Stabilini C., et al. Liver damage in severely obese patients: a clinical‐biochemical‐morphologic study on 1,000 liver biopsies. Obes Surg 2004; 14: 952–8
   Google Scholar
• Angulo P., Keach J. C., Batts K. P., Lindor K. D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356–62
   PubMed Web of Science ®Google Scholar
• Mehta S. H., Brancati F. L., Sulkowski M. S., Strathdee S. A., Szklo M., Thomas D. L. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology 2001; 33: 1554
   PubMed Web of Science ®Google Scholar
• Wilson C. Hepatitis C infection and type 2 diabetes in American‐Indian women. Diabetes Care 2004; 27: 2116–9
   Google Scholar
• Petit J. M., Bour J. B., Galland‐Jos C., Minello A., Verges B., Guiguet M., et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279–83
   PubMed Web of Science ®Google Scholar
• Lecube A., Hernandez C., Genesca J., Esteban J. I., Jardi R., Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 1171–5
   PubMed Web of Science ®Google Scholar
• Aytug S., Reich D., Sapiro L. E., Bernstein D., Begum N. Impaired IRS‐1/PI3‐kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384–92
   PubMed Web of Science ®Google Scholar
• Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Tsukamoto K., Kimura S., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840–8
   PubMed Web of Science ®Google Scholar
• Hourigan L. F., Macdonald G. A., Purdie D., Whitehall V. H., Shorthouse C., Clouston A., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215–9
   PubMed Web of Science ®Google Scholar
• Adinolfi L. E., Gambardella M., Andreana A., Tripodi M. F., Utili R., Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358–64
   PubMed Web of Science ®Google Scholar
• Monto A., Alonzo J., Watson J. J., Grunfeld C., Wright T. L. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729–36
   PubMed Web of Science ®Google Scholar
• Rubbia‐Brandt L., Giostra E., Mentha G., Quadri R., Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha‐interferon. J Hepatol 2001; 35: 307
   Google Scholar
• Kumar D., Farrell G. C., Fung C., George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266–72
   PubMed Web of Science ®Google Scholar
• Serfaty L., Andreani T., Giral P., Carbonell N., Chazouilleres O., Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428–34
   PubMed Web of Science ®Google Scholar
• Perlemuter G., Sabile A., Letteron P., Vona G., Topilco A., Chretien Y., et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral‐related steatosis. FASEB J 2002; 16: 185–94
   PubMed Web of Science ®Google Scholar
• Ratziu V., Munteanu M., Charlotte F., Bonyhay L., Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049–55
   PubMed Web of Science ®Google Scholar
• Bressler B. L., Guindi M., Tomlinson G., Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639–44
   PubMed Web of Science ®Google Scholar
• Lam N. P., Pitrak D., Speralakis R., Lau A. H., Wiley T. E., Layden T. J. Effect of obesity on pharmacokinetics and biologic effect of interferon‐alpha in hepatitis C. Dig Dis Sci 1997; 42: 178–85
   Google Scholar
• Adams L. A., Sanderson S., Lindor K. D., Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132–8
   PubMed Web of Science ®Google Scholar
• Poynard T., Mathurin P., Lai C. L., Guyader D., Poupon R., Tainturier M. H., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257–65
   PubMed Web of Science ®Google Scholar
• Sasaki A. Mortality and causes of death in patients with diabetes mellitus in Japan. Diabetes Res Clin Pract 1994; 24
   Google Scholar
• de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause‐specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756–61
   PubMed Web of Science ®Google Scholar
• El‐Serag H. B., Everhart J. E. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822–8
   PubMed Web of Science ®Google Scholar
• Caldwell S. H., Hespenheide E. E. Subacute liver failure in obese women. Am J Gastroenterol 2002; 97: 2058–62
   PubMed Web of Science ®Google Scholar
• Jepsen P., Vilstrup H., Mellemkjaer L., Thulstrup A. M., Olsen J. H., Baron J., et al. Prognosis of patients with a diagnosis of fatty liver ‐ a registry‐based cohort study. Hepatogastroenterology 2003; 50: 2101–4
   PubMedGoogle Scholar
• Ioannou G. N., Weiss N. S., Kowdley K. V., Dominitz J. A. Is obesity a risk factor for cirrhosis‐related death or hospitalization? a population‐based cohort study. Gastroenterology 2003; 125: 1053–9
   PubMed Web of Science ®Google Scholar
• Dam‐Larsen S., Franzmann M., Andersen I. B., Christoffersen P., Jensen L. B., Sorensen T. I., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750–5
   PubMed Web of Science ®Google Scholar
• Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatol 1994; 21: 317–25
   Google Scholar
• Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh‐Tainturier M. H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis. Hepatology 2002; 35: 1485–93
   PubMed Web of Science ®Google Scholar
• Hui J. M., Kench J. G., Chitturi S., Sud A., Farrell G. C., Byth K., et al. Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420–7
   PubMed Web of Science ®Google Scholar
• Younossi Z. M., Gramlich T., Matteoni C. A., Boparai N., McCullough A. J. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262–5
   PubMed Web of Science ®Google Scholar
• Moller H., Mellemgaard A., Lindvig K., Olsen J. H. Obesity and cancer risk: a Danish record‐linkage study. Eur J Cancer 1994; 30A: 344–50
   PubMed Web of Science ®Google Scholar
• Adami H. O., Chow W. H., Nyren O., Berne C., Linet M. S., Ekbom A., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472–7
   PubMed Web of Science ®Google Scholar
• La Vecchia C., Negri E., Decarli A., Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 1997; 73: 204–7
   PubMedGoogle Scholar
• Wideroff L., Gridley G., Mellemkjaer L., Chow W. H., Linet M., Keehn S., et al. Cancer incidence in a population‐based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360–5
   PubMed Web of Science ®Google Scholar
• Braga C., La Vecchia C., Negri E., Franceschi S. Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer 1997; 33: 629–34
   PubMed Web of Science ®Google Scholar
• Lagiou P., Kuper H., Stuver S. O., Tzonou A., Trichopoulos D., Adami H. O. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096–9
   PubMed Web of Science ®Google Scholar
• El‐Serag H. B., Richardson P. A., Everhart J. E. The role of diabetes in hepatocellular carcinoma: a case‐control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462–7
   PubMed Web of Science ®Google Scholar
• Nair S., Mason A., Eason J., Loss G., Perrillo R. P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 2002; 36: 150–5
   PubMed Web of Science ®Google Scholar
• Calle E. E., Rodriguez C., Walker‐Thurmond K., Thun M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–38
   PubMed Web of Science ®Google Scholar
• Verlato G., Zoppini G., Bonora E., Muggeo M. Mortality from site‐specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 2003; 26: 1047–51
   PubMedGoogle Scholar
• Sorensen H. T., Mellemkjaer L., Jepsen P., Thulstrup A. M., Baron J., Olsen J. H., et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 2003; 36: 356–9
   PubMed Web of Science ®Google Scholar
• Regimbeau J. M., Colombat M., Mognol P., Durand F., Abdalla E., Degott C., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69–73
   PubMedGoogle Scholar
• Coughlin S. S., Calle E. E., Teras L. R., Petrelli J., Thun M. J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160–7
   PubMed Web of Science ®Google Scholar
• Jee S. H., Ohrr H., Sull J. W., Yun J. E., Ji M., Samet J. M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194–202
   PubMed Web of Science ®Google Scholar
• Davila J. A., Morgan R. O., Shaib Y., McGlynn K. A., El‐Serag H. B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533–9
   PubMed Web of Science ®Google Scholar
• Wolk A., Gridley G., Svensson M., Nyren O., McLaughlin J. K., Fraumeni J. F., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13–21
   PubMed Web of Science ®Google Scholar
• Lawson D. H., Gray J. M., McKillop C., Clarke J., Lee F. D., Patrick R. S. Diabetes mellitus and primary hepatocellular carcinoma. QJM 1986; 61: 945–55
   Google Scholar
• Huo T. I., Lui W. Y., Huang Y. H., Chau G. Y., Wu J. C., Lee P. C., et al. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003; 98: 2293–8
   Google Scholar
• Ohata K., Hamasaki K., Toriyama K., Matsumoto K., Saeki A., Yanagi K., et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036–43
   PubMed Web of Science ®Google Scholar
• Yang S., Lin H. Z., Hwang J., Chacko V. P., Diehl A. M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity‐related hepatic steatosis a premalignant condition?. Cancer Res 2001; 61: 5016–23
   PubMed Web of Science ®Google Scholar
• Zen Y., Katayanagi K., Tsuneyama K., Harada K., Araki I., Nakanuma Y. Hepatocellular carcinoma arising in non‐alcoholic steatohepatitis. Pathol Int 2001; 51: 127–31
   PubMed Web of Science ®Google Scholar
• Marrero J. A., Fontana R. J., Su G. L., Conjeevaram H. S., Emick D. M., Lok A. S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349–54
   PubMed Web of Science ®Google Scholar
• Medina J., Fernandez‐Salazar L. I., Garcia‐Buey L., Moreno‐Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057–66
   PubMed Web of Science ®Google Scholar
• Bugianesi E., Zannoni C., Vanni E., Marzocchi R., Marchesini G. Non‐alcoholic fatty liver and insulin resistance: a cause‐effect relationship?. Dig Liver Dis 2004; 36: 165–73
   PubMedGoogle Scholar
• Browning J. D., Horton J. D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147–52
   PubMed Web of Science ®Google Scholar
• Groop L. Genetics of the metabolic syndrome. Br J Nutr 2000; 83( Suppl 1)S39–48
   Google Scholar
• Rich S. S., Concannon P. Challenges and strategies for investigating the genetic complexity of common human diseases. Diabetes 2002; 51( Suppl 3)S288–94
   Google Scholar
• Ashrafi K., Chang F. Y., Watts J. L., Fraser A. G., Kamath R. S., Ahringer J., et al. Genome‐wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 2003; 421: 268–72
   PubMed Web of Science ®Google Scholar
• Sreekumar R., Rosado B., Rasmussen D., Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244–51
   PubMed Web of Science ®Google Scholar
• Marfella R., Quagliaro L., Nappo F., Ceriello A., Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108: 635–6
   PubMed Web of Science ®Google Scholar
• Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067–72
   PubMed Web of Science ®Google Scholar
• Guha M., Bai W., Nadler J. L., Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia‐induced oxidant stress‐dependent and ‐independent pathways. J Biol Chem 2000; 275: 17728–39
   PubMed Web of Science ®Google Scholar
• Svegliati‐Baroni G., Ridolfi F., Di Sario A., Casini A., Marucci L., Gaggiotti G., et al. Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743–51
   PubMed Web of Science ®Google Scholar
• Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738–44
   PubMed Web of Science ®Google Scholar
• Hickman I. J., Powell E. E., Prins J. B., Clouston A. D., Ash S., Purdie D. M., et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39: 1042–8
   PubMed Web of Science ®Google Scholar
• Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752–61
   PubMed Web of Science ®Google Scholar
• Marchesini G., Ronchi M., Forlani G., Bugianesi E., Bianchi G., Fabbri A., et al. Cardiovascular disease in cirrhosis–a point‐prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999; 94: 655–62
   PubMedGoogle Scholar
• Bugianesi E., Marzocchi R., Villanova N., Marchesini G. Non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 2004; 18: 1105–16
   PubMed Web of Science ®Google Scholar
• Neuschwander‐Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202–19
   PubMed Web of Science ®Google Scholar
• Eriksson S., Eriksson K. F., Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986; 220: 83–8
   PubMed Web of Science ®Google Scholar
• Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408–13
   PubMed Web of Science ®Google Scholar
• Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103–7
   PubMed Web of Science ®Google Scholar
• Franzese A., Vajro P., Argenziano A., Puzziello A., Iannucci M. P., Saviano M. C., et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow‐up in an Italian population. Dig Dis Sci 1997; 42: 1428–32
   PubMed Web of Science ®Google Scholar
• Knobler H., Schattner A., Zhornicki T., Malnick S. D., Keter D., Sokolovskaya N., et al. Fatty liver–an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92: 73–9
   PubMed Web of Science ®Google Scholar
• Kugelmas M., Hill D. B., Vivian B., Marsano L., McClain C. J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413–9
   PubMed Web of Science ®Google Scholar
• Hickman I. E., Jonsson J. R., Prins J. B., Ash S., Purdie D. M., Clouston A. D., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413–9
   PubMed Web of Science ®Google Scholar
• Caldwell S. H., Hespenheide E. E., Redick J. A., Iezzoni J. C., Battle E. H., Sheppard B. L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519–25
   PubMed Web of Science ®Google Scholar
• Neuschwander‐Tetri B. A., Brunt E. M., Wehmeier K. R., Oliver D., Bacon B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐gamma ligand rosiglitazone. Hepatology 2003; 38: 1008–17
   PubMed Web of Science ®Google Scholar
• Promrat K., Lutchman G., Uwaifo G. I., Freedman R. J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188–96
   PubMed Web of Science ®Google Scholar
• Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non‐alcoholic steatohepatitis. Lancet 2001; 358: 893–4
   PubMed Web of Science ®Google Scholar
• Uygun A., Kadayifci A., Isik A. T., Ozgurtas T., Deveci S., Tuzun A., et al. Metformin in the treatment of patients with non‐alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537–44
   PubMed Web of Science ®Google Scholar
• Nair S., Diehl A. M., Wiseman M., Farr G. H, Jr., Perrillo R. P. Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23–8
   PubMed Web of Science ®Google Scholar
• Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082–90
   PubMed Web of Science ®Google Scholar
• Neuschwander‐Tetri B. A., Brunt E. M., Wehmeier K. R., Sponseller C. A., Hampton K., Bacon B. R. Interim results of a pilot study demonstrating the early effects of the PPAR‐gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non‐alcoholic steatohepatitis. J Hepatol 2003; 38: 434–40
   PubMed Web of Science ®Google Scholar
• Tiikkainen M., Hakkinen A. M., Korsheninnikova E., Nyman T., Makimattila S., Yki‐Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169–76
   PubMed Web of Science ®Google Scholar
• Ezzati M., Lopez A. D., Rodgers A., Vander Hoorn S., Murray C. J. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–60
   PubMed Web of Science ®Google Scholar
• Marchesini G., Trovati M. Type 2 diabetes and the Naaman syndrome. Diabetes Care 2003; 26: 3195
   Google Scholar
• Ezzati M., Hoorn S. V., Rodgers A., Lopez A. D., Mathers C. D., Murray C. J. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362: 271–80
   PubMed Web of Science ®Google Scholar